Genentech Oncology
The immune system plays a crucial role in protecting the body against cancer by recognizing and destroying cells it perceives as foreign. Cancer immunity strategies aim to restore the immune system's abilities to mobilize an antitumor immune response.1
Some strategies aim to override the mechanisms that prevent T cells from mounting an immune response. Some aim to negate the mechanisms that prevent T cells from infiltrating the tumor microenvironment. Others seek to stimulate an immune response, thereby strengthening detection and destruction of newly transformed or developing tumors and reducing the likelihood of further tumor growth and metastases.1,2
Since multiple immune inhibitory mechanisms are often present concurrently, we aim to evaluate and develop diverse combination strategies to optimize the antitumor immune response.3
Our scientists believe that human cancers can be characterized by 3 distinct immune phenotypes. These phenotypes describe the level of T-cell presence and activity in the tumor microenvironment, and help to inform strategies for initiating or restoring the antitumor immune response in patients with cancer.2,4
The classification of these 3 immune phenotypes provides a foundation for tailoring the right approach to the right patient, and is fundamental to supporting the development of novel combination strategies.2
In this immune phenotype, there is a lack of pre-existing immunity.
*External partner.
In this immune phenotype, there is some pre-existing immunity, but T cells are at the periphery of tumors.
*External partner.
In this immune phenotype, pre-existing immunity is present at the tumor site.
*Tumor cell killing by CD8+ T cells.
†External partner.
Based upon years of fundamental research, our scientists have identified a unifying framework called the “cancer immunity cycle”—a 7-step process that describes how healthy immune systems can recognize and eradicate cancer.
A patient with cancer may experience disruption at one or more steps of the cancer immunity cycle. As a result, a multitarget combination or sequencing strategy may be required to initiate or reinitiate a self-sustaining cycle of cancer immunity.
With this scientific framework, we are able to spearhead a more systematic approach to cancer immunity research—with the aim of a more personalized strategy for patients with cancer.
The cycle starts with antigen release. Neoantigens are released as a result of tumorigenesis and captured by dendritic cells for processing. Additional immunogenic signals may include proinflammatory cytokines and factors released by dying tumor cells or by the gut microbiota.
The next step in the process is antigen presentation. Dendritic cells present to T cells the captured antigens on major histocompatibility complex (MHC) I and MHC II molecules.
The presentation of antigens on MHC I and MHC II leads to priming and activation of effector T-cell responses against the cancer-specific antigens that are perceived to be foreign. The nature of the immune response is determined at this stage by the ratio of T-effector cells versus T-regulatory cells.
Now that the antitumor T cells have been activated, they enter the bloodstream and travel through the body to the tumor bed.
When the activated antitumor T cells arrive at a location where a tumor cell is present, they infiltrate the tumor.
Now the T cells are in the tumor microenvironment. The activated effector T cells specifically recognize and bind to cancer cells through the interaction between their T-cell receptor (TCR) and their cognate antigen bound to MHC I.
The last step in the cycle is T-cell–mediated killing* of tumor cells. In this important step, the activated effector T cells kill* their target tumor cells. The killing of the cancer cells releases additional tumor-associated antigens, increasing the breadth and depth of the immune response in subsequent revolutions of the cycle.
*Tumor cell killing by CD8+ T cells.
Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1-10. PMID: 23890059
Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1-10. PMID: 23890059
Kim JM, Chen DS. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann Oncol. 2016;27:1492-1504. PMID: 27207108
Kim JM, Chen DS. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann Oncol. 2016;27:1492-1504. PMID: 27207108
Gajewski TF. The next hurdle in cancer immunotherapy: overcoming the non-T cell-inflamed tumor microenvironment. Semin Oncol. 2015;42:663-671. PMID: 26320069
Gajewski TF. The next hurdle in cancer immunotherapy: overcoming the non-T cell-inflamed tumor microenvironment. Semin Oncol. 2015;42:663-671. PMID: 26320069
Hegde PS, Karanikas V, Evers S. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin Cancer Res. 2016;22:1865-1874. PMID: 27084740
Hegde PS, Karanikas V, Evers S. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin Cancer Res. 2016;22:1865-1874. PMID: 27084740
Roche. 2023 Q1 results. April 26, 2023. Accessed May 10, 2023. https://assets.cwp.roche.com/f/126832/x/469b6bc1c5/irp230426-a.pdf
Roche. 2023 Q1 results. April 26, 2023. Accessed May 10, 2023. https://assets.cwp.roche.com/f/126832/x/469b6bc1c5/irp230426-a.pdf
The compounds and their uses mentioned on this website are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. Do you wish to proceed?
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.